Biophytis S.A. (ALBPS) - Total Liabilities
Based on the latest financial reports, Biophytis S.A. (ALBPS) has total liabilities worth €14.44 Million EUR (≈ $16.88 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biophytis S.A. - Total Liabilities Trend (2012–2024)
This chart illustrates how Biophytis S.A.'s total liabilities have evolved over time, based on quarterly financial data. See ALBPS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Biophytis S.A. Competitors by Total Liabilities
The table below lists competitors of Biophytis S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Omkar Speciality Chemicals Limited
NSE:OMKARCHEM
|
India | Rs2.43 Billion |
|
First Tin PLC
LSE:1SN
|
UK | GBX573.22K |
|
Crystal Amber Fund Limited
LSE:CRS
|
UK | GBX354.05K |
|
Shanti Overseas (India) Limited
NSE:SHANTI
|
India | Rs142.01 Million |
|
Kodal Minerals PLC
LSE:KOD
|
UK | GBX208.32K |
|
Eco Animal Health Group Plc
LSE:EAH
|
UK | GBX21.57 Million |
|
Calnex Solutions Plc
LSE:CLX
|
UK | GBX9.34 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Biophytis S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biophytis S.A. stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.08 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biophytis S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biophytis S.A. (2012–2024)
The table below shows the annual total liabilities of Biophytis S.A. from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €16.60 Million ≈ $19.41 Million |
+4.76% |
| 2023-12-31 | €15.85 Million ≈ $18.53 Million |
-33.68% |
| 2022-12-31 | €23.90 Million ≈ $27.94 Million |
-21.79% |
| 2021-12-31 | €30.56 Million ≈ $35.72 Million |
+49.95% |
| 2020-12-31 | €20.38 Million ≈ $23.82 Million |
-19.13% |
| 2019-12-31 | €25.20 Million ≈ $29.46 Million |
+69.61% |
| 2018-12-31 | €14.86 Million ≈ $17.37 Million |
+212.04% |
| 2017-12-31 | €4.76 Million ≈ $5.57 Million |
+22.90% |
| 2016-12-31 | €3.87 Million ≈ $4.53 Million |
+109.34% |
| 2015-12-31 | €1.85 Million ≈ $2.16 Million |
+22.09% |
| 2014-12-31 | €1.52 Million ≈ $1.77 Million |
+46.15% |
| 2013-12-31 | €1.04 Million ≈ $1.21 Million |
-4.36% |
| 2012-12-31 | €1.08 Million ≈ $1.27 Million |
-- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more